drugset
drugset / Trial / NCT04882176

A Clinical Study Preliminary Efficacy of LM-061 Tablet in Subjects With Advanced Tumours

NCT04882176 ↗

Phase 1/2 Terminated 18 enrolled LaNova Medicines Limited
Non-randomizedSequentialOpen-labelTreatment

Summary

This is a phase I/II, open-label, dose escalation and dose extension study to evaluate the safety, tolerability, PK, and preliminary efficacy of LM-061 in subjects with advanced tumors.

Timeline

Start
2021-05-20
Primary completion
2023-02-07
Completion
2023-07-19

Drugs

EvaluationDrugModalityDoseRoute
Subject LM-061 Unknown 2.5 mg Oral
Subject LM-061 Unknown 5 mg Oral
Subject LM-061 Unknown 10 mg Oral
Subject LM-061 Unknown 20 mg Oral
Subject LM-061 Unknown 30 mg Oral
Subject LM-061 Unknown 40 mg Oral
Subject LM-061 Unknown 60 mg Oral

Indications

No indication recorded.